Series A+ · Biotech
Syntax Bio: Series A+
Develops cell therapies using proprietary Cellgorithm platform for regenerative medicine
Funding history
Series A+ · This round$14.4M
Develops cell therapies using proprietary Cellgorithm platform for regenerative medicine